5-Amino-1MQ
Also known as: 5-amino-1-methylquinolinium, NNMT Inhibitor
Popular For
Fat metabolism, cellular energy, body composition
Key Facts: 5-Amino-1MQ
- Category
- Weight Loss
- FDA Status
- Not FDA Approved
- Clinical Status
- Preclinical Research
- Administration
- Subcutaneous injection or oral
- Typical Dose
- 50-75 mg daily
- Frequency
- Once daily, morning
- Evidence Level
- Animal Studies
- Duration
- 4-6 weeks (cycling recommended)
Mechanism of Action
5-Amino-1MQ inhibits NNMT, an enzyme that regulates NAD+ and SAM (S-adenosyl methionine) levels. By blocking NNMT, it increases NAD+ availability, enhancing mitochondrial function, promoting fat oxidation, and supporting cellular energy metabolism. It does not affect appetite or food intake.
Research Summary
Mouse studies showed over 30% decrease in adipocyte size and 40% decrease in adipocyte volume. Treated mice had 30% lower total cholesterol. No significant impact on food intake or adverse effects observed. Human clinical data remains limited.
Dosing Information
Note: Animal study doses may not translate directly to humans.
Typical Dosingⓘ
Community experience
50-75 mg daily
50-100 mg daily
Once daily, morning
Small molecule NNMT inhibitor. Cycle 4-6 weeks on, 2-4 weeks off. Weight-based: <150 lbs: 50-75mg, 150-200 lbs: 75mg, >200 lbs: 75-100mg.
Research Dosingⓘ
Scientific studies
Research compound - not FDA approved
Doses from Studies
20 mg/kg/day (mice)
Duration
4-6 weeks (cycling recommended)
Administration
Subcutaneous injection or oral
Timing & Administration
Best Time to Take
Morning, fasted
Once daily
Food Recommendation
With or without food
Why This Timing?
Morning administration aligns with natural metabolic rhythm and minimizes potential sleep disruption
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Mild headache (initial dosing)
- ●Nausea
- ●Increased alertness/jitteriness
- ●Rare: insomnia
- ●Rare: elevated blood pressure
References
Related Peptides
Peptides commonly compared with 5-Amino-1MQ or used in similar applications.
Semaglutide
FDAA GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Weight LossTirzepatide
FDAA dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
Weight LossRetatrutide
Clinical TrialsA triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.
Weight LossOrforglipron
Clinical TrialsAn oral non-peptide GLP-1 receptor agonist. NDA under FDA review with decision expected April 10, 2026. If approved, will compete directly with oral Wegovy.
Weight LossCagriSema
Clinical TrialsA combination of semaglutide and cagrilintide (amylin analog). The most effective weight loss drug candidate, showing 22.7% body weight reduction in Phase 3 trials - superior to any single-agent GLP-1.
Weight LossLiraglutide
FDAAn FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.
Weight LossLooking for a trusted vendor?
Pro members get access to verified vendors with quality standards & exclusive discount codes.
Want updates on 5-Amino-1MQ research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.